Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF93T2)

• Drug Name: Anti-CD19/BCMA CAR-T cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMF93T2

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[5]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[6]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[7]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[8]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[9]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[10]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[11]

Drug(s) Targeting B-cell maturation protein (TNFRSF17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Idecabtagene vicleucel	DMP1QTS	Multiple myeloma	2A83	Approved	[12]
Belantamab mafodotin	DMBT3AI	Multiple myeloma	2A83	Approved	[13]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[14]
Teclistamab	DMGR8JI	Multiple myeloma	2A83	Approved	[15]
Ciltacabtagene autoleucel	DMU2J7Y	Multiple myeloma	2A83	Phase 3	[16]
Bb2121	DMB0UF9	Multiple myeloma	2A83	Phase 2	[17]
LCAR-B38M CAR-T Cell	DMQZJNA	Multiple myeloma	2A83	Phase 2	[18]
Descartes-08	DM63P1W	Multiple myeloma	2A83	Phase 2	[19]
Descartes-11	DM1UO4S	Multiple myeloma	2A83	Phase 2	[20]
CART-19/BCMA	DMVW1GY	Multiple myeloma	2A83	Phase 1/2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell maturation protein (TNFRSF17)	TTZ3P4W	TNR17_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [8] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [9] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [10] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [11] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [14] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [15] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
• [16] ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
• [19] ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
• [20] Clinical pipeline report, company report or official report of Cartesian Therapeutics.
• [21] ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT